Jason S. Fisherman

Jason S.
Fisherman founded Synthesis Capital in 2007, where he worked as Managing Director from 2012 to 2018 and Synkine Therapeutics, Inc. in 2018, where he is working as President & Chief Executive Officer from 2018.
Dr. Fisherman also currently works at White Cube Management LLC, as Managing Director from 2007 and AlloMek Therapeutics LLC, as Director from 2018.
Dr. Fisherman also formerly worked at C4 Therapeutics, Inc., as President, Chief Executive Officer & Director in 2016, Spherics, Inc., as Chairman, Advent International LP, as Managing Director from 1994 to 2007, Enzon Pharmaceuticals, Inc., as Senior Director-Medical Research from 1991 to 1994, ILEX Oncology, Inc., as Director, Exelixis, Inc., as Director, Anadys Pharmaceuticals, Inc., as Director, Achillion Pharmaceuticals, Inc., as Independent Director from 2000 to 2020, Cellzome Ltd., as Director, Aegerion Pharmaceuticals, Inc., as Director from 2005 to 2011, Trident Pharmaceuticals, Inc., as Director, Ampla Pharmaceuticals, Inc., as Director, Prexa Pharmaceuticals, Inc., as Director, Oridion Systems Ltd., as Director from 1997 to 2003, MDeverywhere, Inc., as Director, Nereus Pharmaceuticals, Inc., as Director, Cellzome AG, as Director, TorreyPines Therapeutics, Inc., as Director from 2006 to 2009, TPTX, Inc., as Director from 2000 to 2007, Spear Therapeutics Ltd., as Director, Crucell NV, as Member-Supervisory Board, Dana-Farber Cancer Institute, Inc., as Research Fellow, and National Cancer Institute, as Principal in 1991.
Dr. Fisherman received his doctorate degree from the University of Pennsylvania, undergraduate degree from Yale University, and Masters Business Admin degree from The Wharton School of the University of Pennsylvania.